ENDOPREDICT

Protein biomarker for the prediction of response to endocrine treatment in breast cancer patients

Coordinatore	ROYAL COLLEGE OF SURGEONS IN IRELAND    more  Organization address address: Saint Stephen's Green 123 city: DUBLIN postcode: 2 contact info Titolo: Prof. Nome: Leonie Cognome: Young Email: send email Telefono: +353 1 4028576
Nazionalità Coordinatore	Ireland [IE]
Totale costo	570˙313 €
EC contributo	570˙313 €
Programma	FP7-PEOPLE Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	FP7-PEOPLE-2012-IAPP
Funding Scheme	MC-IAPP
Anno di inizio	2013
Periodo (anno-mese-giorno)	2013-02-01   -   2017-01-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	ROYAL COLLEGE OF SURGEONS IN IRELAND  Organization address address: Saint Stephen's Green 123 city: DUBLIN postcode: 2 contact info Titolo: Prof. Nome: Leonie Cognome: Young Email: send email Telefono: +353 1 4028576	IE (DUBLIN)	coordinator	390˙695.03
2	ALMAC DIAGNOSTICS LIMITED  Organization address address: SEAGOE INDUSTRIAL ESTATE 20 city: CRAIGAVON postcode: BT63 5QD contact info Titolo: Dr. Nome: Karen Cognome: Keating Email: send email Telefono: +44 28 38395982	UK (CRAIGAVON)	participant	179˙618.56

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Classical pathologic parameters have been used to inform adjuvant clinical treatment choices for early breast cancer patients. There remain a significant number of patients however, who despite a reportedly favourable prognostic profile, experience metastatic disease. Elucidation of the mechanisms of tumour adaptability and the identification of predictive markers of early recurrence is the basis of personalized medicine. Work from our group has established the developmental protein HOXC11 as a powerful predictor of resistance to endocrine treatment in breast cancer patients .The aim of this project is to establish a joint industry-academia partnership to produce a commercially viable and clinically validated predictive assay/kit which based on the use of HOXC11 as a predictive biomarker of poor response to endocrine treatment in breast cancer patients.'